Insights | Meridian Research Group | Page 3

340B Drug Discount Program

The Health Resources and Services Administration (HRSA) has begun accepting applications for a voluntary 340B Rebate Model Pilot Program that will allow drug manufacturers to provide 340B-discounted drug prices using a rebate mechanism. The pilot is set to begin January 1, 2026 and last at least one year. In practice, such rebate models have the...

The Center for Medicare & Medicaid Innovation (CMMI) is in the process of developing a demonstration program which would test allowing Medicare Part D plans and state Medicaid program to cover GLP-1 products for weight loss purposes. Reports suggest the demonstration could begin as soon as Q2 next year for state Medicaid programs (~2027 for...

Drug Pricing/Most-Favored Nation

The Trump administration is escalating its efforts to compel drugmakers to offer most-favored nation (MFN) prices to American consumers (i.e., prices equivalent to those offered in the markets of countries comparable to the U.S. economically/developmentally). In recent days, the White House issued letters to more than a dozen drugmakers demanding...

Medicare Hospice Reimbursement

As part of the FY26 hospice final rule, CMS will increase hospice payments by 2.6% ($750m) relative to FY25 levels and set the annual per beneficiary payment cap at $35,361.44 (increased from $34,465.34 in FY25).

Medicare Skilled Nursing Facility (SNF) Reimbursement

As part of the FY26 SNF final rule, CMS will increase SNF payments by 3.2% ($1.16b) relative to FY25.

Medicare Inpatient Hospital (IPPS) Reimbursement

As part of the FY26 IPPS final rule, CMS will increase inpatient hospital payments by 2.8% ($4b) relative to FY25.